FEATURES OF THE COMMUNITY–ACQUIRED PNEUMONIA IN A CHILD WITH KASABACH-MERRITT SYNDROME: CASE-REPORT AND MINI-REVIEW

Oksana BOYARCHUK1, Andrii CHORNOMYDZ2✉, Iryna CHORNOMYDZ1

1 Department of Children's Diseases and Pediatric Surgery, I. Horbachevsky Ternopil State Medical University, Ternopil, Ukraine
2 Department of Pharmacology and Clinical Pharmacology, I. Horbachevsky Ternopil State Medical University, Ternopil, Ukraine

Received 3 Febr 2019, Corrections received 23 Apr 2019, Accepted 30 Apr 2019

https://doi.org/10.31688/ABMU.2019.54.2.28

Address for correspondence: Andrii CHORNOMYDZ
Department of Pharmacology and Clinical Pharmacology, I. Horbachevsky Ternopil State Medical University, Ternopil, Ukraine
Address: 1, Maydan Voli, Ternopil, 46001, Ukraine
E-mail: chornomydz@tdmu.edu.ua

Abstract

Introduction. The Kasabach-Merritt syndrome is a rare and severe disease that occurs in children in the presence of a large-sized hemangioma, accompanied by coagulation disorders. This disease complicates the course of many somatic diseases in children, including community-acquired pneumonia, due to the clotting disorder.

Case presentation. A case of a 4.5-month-old child with a combination of capillary hemangioma of the dextral chest surface, complicated by Kasabach-Merritt syndrome, and community-acquired right-sided focal pneumonia is presented. The possible effect of the Kasabach-Merritt syndrome on the course of community-acquired pneumonia has been analyzed. Additionally, the drugs’ effect on the coagulation disorder, the state of hemangioma, and the course of community-acquired pneumonia in children have been investigated.

Conclusions. Severe coagulation disorders may occur in patients with Kasabach-Merritt syndrome and community-acquired pneumonia. Constant monitoring is necessary.
essential during hospitalization. Such combination of diseases should be treated considering the ability of the drugs to influence both the hemostasis system and the progression of hemangioma’s growth.

**Keywords:** Kasabach-Merritt syndrome, hemangioma, community-acquired pneumonia, children, clotting disorder.

**Case presentation**

We report the case of a 4.5-month-old girl, who was admitted to Ternopil Regional Children’s Hospital, Ukraine, complaining of wet cough, decreased appetite, body temperature up to 37.2° C. The history showed that the child had concretion and soft-tissue swelling in the area of the dextral lateral surface of the breast since birth. At the age of 2 months, in the center of the concretion, which was gradually increasing and reached 10x8 cm, the skin turned into blue-cherry color without sharp contours and 2 cm in diameter. After specialists’ examination and follow-up examination, a capillary hemangioma of the dextral lateral surface of the breast was diagnosed. Three days after, an altered general condition was noted: subfebrility, restlessness, appetite loss and general weakness appeared, the hematoma covered most dextral half of the trunk and dextral lower limb. Kasabach–Merritt syndrome was diagnosed: cavernous hemangioma of the dextral chest wall; severe thrombocytopenia; moderate post-hemorrhagic anemia; hemorrhagic syndrome: hematoma of the dextral half of the trunk, subcutaneous hematoma of the extremities, dextral hemothorax (drainage of the dextral pleural cavity). The packed red cell transfusion, fresh frozen plasma transfusion and platelet transfusion, anticoagulation reversal, antimicrobial therapy, and glucocorticosteroids were prescribed. As a result of the treatment, the general status
improvement was noticed and the child was referred to the Republican Center on Pediatric Hematology «Okhmatdyt», Ukraine. In the clinic, the diagnosis has been confirmed and it has been established that the surgical removal of the hemangioma is impossible, due to the large volume of neoplasm and germination in surrounding tissues. The conservative treatment with corticosteroids and propranolol was assigned. A post-discharge improvement in child’s health was noticed, the tumor marginally decreased in size, the signs of hemorrhagic syndrome subsided.

Five days before the current admission to the hospital, the child’s condition has deteriorated, and the above-mentioned complaints have appeared. On physical examination, the general child’s condition was moderately severe. She had visible mucous membranes of pale pink color, infiltration of the skin with a red-blue color and poorly demarcated round shape, 7 cm in diameter, was noted in the area of the dextral surface of the chest (Fig. 1). There were petechiae hemorrhages and signs of intradermal hemorrhages around the navel extending over the entire surface of the dextral half of the trunk, with the transition to the back and the anterior abdominal wall. The tumor was elastic, akinetic, with no evidence of inflammation on palpation. The patient was eupneic, with nasal breathing, frequency of respiratory movements – 42 per minute, dullness on percussion over the lungs in the lower sections of the right and between the shoulder blade was concluded. By auscultation – crackles and crepitations were heard on the right hemithorax, in the lower sections. The cardiac sounds were rhythmic, with a heart rate of 132 beats per minute. No pathological findings were detected at the abdominal examination. Bowel and bladder habits were normal. At chest X-ray examination, a consolidation in the basal segments of the right lung was observed, with increased pulmonary vascularity. Blood tests revealed anemia (hemoglobin 9.0 g/dL), thrombocytopenia (118 x 10^9/dL), normal leukocytes and no increase in the number of immature forms of neutrophilic leukocytes. C-reactive protein – 6 mg/dL. The biochemical analysis of blood and urine were normal. The ultrasound examination revealed a small amount of fluid in the right pleural sinus. The child consulted a hematologist, a cardiologist, an oncologist, a thoracic surgeon, and other specialists. She was diagnosed with community-acquired right-focal pneumonia, and Kasabach–Merritt syndrome: cavernous hemangioma of the right chest wall, mild thrombocytopenia, moderate anemia.

Conservative treatment was initiated, including antimicrobial therapy (amoxicillin + clavulanic acid (daily dose - 40 mg/5 mg per kg) intravenously, expectorants (ambroxol, daily dose – 15 mg), oxygen therapy, vitamin E 0.5 ml of 10% solution per day, aminocaproic acid 5% - 2.5 ml, 4 times a day. During follow-up, the amelioration of clinical signs was noticed, but during the 4th day, the platelet level decreased to 98x10^9/dL. Glucocorticoids were added to treatment (prednisolone 2.5 mg per kg per day). The condition of the child improved, a positive change on the X-ray was established, and the level of platelets by the end of treatment was 209x10^9/dL. The duration of the antibiotic therapy was 10 days, the length of hospital stay – 12 days. The child was discharged in satisfactory condition.

**DISCUSSION**

The Kasabach-Merritt syndrome was first described by Haig Haiguni Kasabach and Katharine Krom Merritt in 1940, when they observed infants with gigantic capillary hemangiomas and thrombocytopenic purpura. This is a rather rare pathology and the total number of described cases was toward 200. Every major hemangioma doesn’t have to be accompanied by the development of KMS. The mortality rate is less than 10% in cases of skin lesions and reaches 60% in the presence of retroperitoneal tumors.
The exact etiology and pathogenesis of the disease are unknown, but in some cases, the hereditary pattern of this pathology has been discovered, autosomal dominant type, although some papers deny this. By mechanism, the processes that occur in hemangioma are the chronic form of disseminated intravascular blood coagulation. Blood circulation slowing, with a large number of microtubes and increased use of platelets occurs in a giant hemangioma, which has a branched vascular network. The coagulopathy occurs preferentially due to the defects in the endothelium of the vessels inside hemangioma, which cause platelet activation. In normal conditions, the vascular endothelium prevents thrombocytopenia in many ways. The endothelium damage or its dysfunction is a key factor in platelet activation inside hemangioma in the Kasabach-Merritt syndrome. The blood flow abnormality inside hemangioma due to excessive blood transfusion contributes more to the platelets activation. As a result, secondary (acquired, symptomatic) thrombocytopenia and coagulopathy develop, which are associated with an increase in blood loss in hemangiomas. Thrombocytopenia contributes to the reduction of thrombocyte production, as the functional depletion of reserves occurs, connected with the constant increased destruction of platelets in hemangioma.

Sometimes, the diagnosis of Kasabach-Merritt syndrome is not difficult, due to the tumor predominant localization on the skin surface, as in our case, and the presence of blood clotting disruption signs. The disorders which occur due to thrombocytopenia lead to spontaneous bleeding accompanied by ecchymoses, petechiae and hemangioma’s rapid size increase. In case of severe thrombocytopenia, the bleeding from the mucous membrane of the nasal cavity and the gastrointestinal tract, with subsequent development of severe anemia may occur.

In the context of the described clinical picture, there were also multiple signs of disruption of blood coagulation (petechiae and extensive intradermal hemorrhages) (Fig. 2). Therefore, in Kasabach-Merritt syndrome and another disease (in our case, community-acquired pneumonia), one should be prepared for the complications associated with the risk of hemorrhagic syndrome. In case of pneumonia, the development of a severe hemorrhagic process in lungs, intra-pulmonary haemorrhage, hemotherax and other organs hemorrhage (gastrointestinal tract, hematuria, etc.) may be encountered. Due to the absence of a severe clinical course of pneumonia, our patient did not have such complications.

Nevertheless, an important issue is the choice of the most appropriate treatment in the presence of such combination of pathological processes. The difficulties in choosing the right treatment are based on several important points:

1. Can the drugs used for the Kasabach-Merritt syndrome treatment (or gigantic capillary hemangiomas) increase the risk of pneumonia?
2. Can the drugs used for the Kasabach-Merritt syndrome treatment (or gigantic capillary hemangiomas) complicate the course of community-acquired pneumonia in children?
3. Can the drugs used for pneumonia treatment worsen the course of the Kasabach-Merritt syndrome?

Taking into consideration the fact that the various therapy methods of the Kasabach-Merritt syndrome have shown ambiguous results, there are still no optimal treatment modalities. The reason is the rarity of the syndrome and the low effectiveness of the suggested treatment modality, the percentage of positive results of their usage does not exceed 50%.

Involution of the tumor and correction of life-threatening coagulopathy are the main objectives of the treatment of Kasabach-Merritt syndrome. Currently, different options of treatment are suggested, which include pharmacological therapy, vascular embolisation, radiation therapy and surgical removal of the tumor.

Despite the radicality of the previously described treatment modalities, the most commonly used are drugs which facilitate the hemangioma involution (Table 1).
Hormonotherapy with corticosteroids for the Kasabach-Merritt syndrome in children should be considered as a primary treatment method, if the surgery cannot be performed\cite{1,17,20,21}. However, these drugs effectiveness, as indicated by most researchers, is ambiguous\cite{6,19}. Additionally, after dose interruption, a rapid tumor growth occurs, hence the need for repeated courses of treatment, with increased risk of side effects\cite{6}. Corticosteroids accelerate the symptoms disappearance, reduce the incidence of relapse of the disease, can improve the parameters of alveolar-arterial oxygen transfer and reduce the need for artificial ventilation of lungs\cite{24}.

Hormonotherapy failure. Combined modality treatment using specified drug groups (steroids, IFNα, and propranolol) is the most commonly suggested\cite{19}. Currently, propranolol is a first-line drug in the gigantic hemangiomas treatment without Kasabach-Merritt syndrome. In our case, before hospitalization, the child received combined therapy with corticosteroids and propranolol, and according to information provided by mother and medical records, a positive clinical effect was observed (hemangioma's size reduction and reduction of the hemorrhagic syndrome manifestations).

It should be noted that almost all drugs used for the Kasabach-Merritt syndrome treatment can increase the risk of pneumonia, by immune depression and opportunistic infection development. This particularly concerns the use of corticosteroids, vincristine, and interferon.

Impaired coagulation correction is also an important treatment for the Kasabach-Merritt syndrome. The lack of precise information on the etiology of coagulopathy has led to the application of both substitution therapy and drugs used for disseminated intravascular blood coagulation treatment (antiplatelet therapy, anticoagulants, fibrinolysis inhibitors, etc.)\cite{31}. Heparin and antiplatelet therapy in the Kasabach-Merritt syndrome treatment have problematic success\cite{6,14,21}. The best results have been observed with the usage of fibrinolysis inhibitors, such as tranexamic acid and ypsilon-aminocaproic acid\cite{14,21}. In our case, γ-aminocaproic acid in particular was used for the treatment.

As many researchers consider, the transfusion of plasma and platelets is the basis of the Kasabach-Merritt syndrome treatment\cite{25}. Blood transfusion should be retained if there is no evidence of bleeding, since cytokines from the transfusive blood can aggravate the angiogenic process and lead to increase in hemangioma’s size\cite{21}.

Another important issue is the impact of medications used for the community-acquired pneumonia treatment on the KMS course. The antibacterial agents, anti-inflammatory therapy and expectorants form the basis of the community-acquired pneumonia treatment\cite{26}. Antibiotics of different groups are one of the main medications that can actively influence...
coagulation, and in particular platelet hemostasis\textsuperscript{27}. Thus, antibiotics of the aminoglycoside structure increase the platelet adhesion\textsuperscript{28}.

The penicillin suppresses platelet aggregation and reaction of biologically active substances release, blocking the ability of platelets to convert the arachidonic acid into thromboxanes. Besides, it arrests $\alpha_2$ adrenoreceptors that causes the loss of affinity for thrombocyte $A_2$ and prostaglandin $H_2$, and leads to an ionized calcium concentration decrease in platelets. These effects explain the irreversible inhibition of platelet functions in vitro and in vivo experiments\textsuperscript{29}. The cephalosporins disrupt platelet functions, as they can affect the platelet aggregation, inhibiting the action of aggregation agonists (ADP, collagen)\textsuperscript{30,31}.

There are publications that report the lack of semi-synthetic $\beta$-lactam antibiotics effect on hemostasis\textsuperscript{12,31}. Taking into consideration this fact, we chose the antibiotic amoxicillin in combination with clavulanic acid, as an agent with the least effect on coagulation, for the community-acquired pneumonia treatment in our patient.

**Conclusions**

The Kasabach-Merritt syndrome is a severe disease that can lead to severe complications and significant deterioration of the course of other diseases, such as community-acquired pneumonia in children. This occurs due to coagulation disorders that contribute to the development of severe hemorrhagic complications. Such combination of diseases should be treated considering the drugs effects on both hemostasis system and progression of hemangioma’s growth.

**Compliance with Ethics Requirements:**

"The authors declare no conflict of interest regarding this article"

"The authors declare that all the procedures and experiments of this study respect the ethical standards in the Helsinki Declaration of 1975, as revised in 2008(5), as well as the national law. Informed consent was obtained from the patient included in the study"

"No funding for this study"

**References**

1. North PE. Pediatric vascular tumors and malformations. Surgical Pathology Clinics, 2010;3(3):455–494.
2. Kollipara R, Dinneen L, Rentas KE, et al. Current classification and terminology of pediatric vascular anomalies. American Journal of Roentgenology. 2013;201(5):1124-1135.
3. Arunachalam P, Ravi Kumar VR, Divya S. Kasabach-Merritt syndrome with large cutaneous vascular tumors. J Indian Assoc Pediatr Surg. 2012;17(1):33-36.
4. Habif TP. Vascular tumors and malformations, 5th ed. St. Louis: Mosby Elsevier; 2009: p. 23.
5. Kwok-Williams M, Perez Z, Squire R, Glaser A, Biew S, Taylor R. Radiotherapy for life-threatening mediastinal haemangioma with Kasabach-Merritt syndrome. Pediatr Blood Cancer. 2007;49:739-744.
6. Oksiuta M, Matusczek E, Dąbek W, Zdienis-Koronkiewicz E, Hermanowicz A. Successful exclusive propranolol therapy in an infant with life-threatening Kasabach-Merritt syndrome. J Pediatr Surg. 2013;48(1):200–202.
7. Wang P, Zhou W, Tao L, Zhao N, Chen X-W. Clinical analysis of Kasabach-Merritt syndrome in 17 neonates. BMC Pediatrics. 2014;14:146.
8. Osman NM. Kasabach–Merritt syndrome: a case report. Sudan J Paediatr. 2013;13(1):49-52.
9. Dhandore PD, Hombalkar NN, Pancholi CK. Kasabach Merritt syndrome: is there a role of surgery? J Clin Neonatol. 2016;5:58-60.
10. Maguiness S, Guenther L. Kasabach-Merritt syndrome. Journal of Cutaneous Medicine & Surgery. 2002;6:335–339.
11. Jain TP, Sharma R, Gupta R. Subcutaneous hemangiomas causing Kasabach-Merritt syndrome – MRI features. J Radiol Imaging. 2008;18(4):295–297.
12. Mahajan P, Margolin J, Iacobas I. Kasabach-Merritt phenomenon: classic presentation and management options. Clinical Medicine Insights: Blood Disorders. 2017;10:1-5.
13. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction. Circulation. 2007;115:1285-1295.
14. Larsen EC, Zinkham WH, Eggleston JC, Zitelli BJ. Kasabach-Merritt syndrome: therapeutic considerations. Pediatrics. 1987;79(6):971-980.
15. Hall GW. Kasabach-Merritt syndrome: pathogenesis and management: review. British Journal of Haematology. 2001;112:851-862.
16. Kelly M. Kasabach-Merritt phenomenon. Pediatr Clin N Am. 2010;57:1085–1089.
17. Butorina AV, Shafaranyov VV. Rol gromonoterapii v lechenii sindroma Kazabakha-Merritt u detey. Lechashchyi vnas. 1999;8: 28-30. [Russian]
18. Abass K, Saad H, Kherala M, Abd-Elsayed AA. Successful treatment of Kasabach-Merritt syndrome with vincristine and surgery: a case report and review of literature. Cases J. 2008;1:9.
19. Kim JA, Choi YB, Yi ES, et al. Excellent outcome of medical treatment for Kasabach-Merritt syndrome: a single-center experience. Blood Res. 2016;51(4):256-260.
20. Moura R, Sobreira ML. Kasabach-Merritt syndrome: clinical vs. surgical treatment. J Vasc Bras. 2014;13(4):330-335.
21. Yadav D, Maheshwari A, Aneja S, Seth A, Chandra J. Neonatal Kasabach-Merritt phenomenon. Indian J Med Paediatr Oncol. 2011;32(4):238-241.
22. Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol. 2010;49(3):39-48.
23. Jiang RS, Hu R. Successful treatment of Kasabach-Merritt syndrome arising from kaposiform hemangioendothelioma by systemic corticosteroid therapy and surgery. Int J Clin Oncol. 2012;17:512–516.
24. Chen Y, Li K, Pu H, Wu T. Corticosteroids for pneumonia. Cochrane Database of Systematic Reviews. 2011;3:CD007729.
25. Henley J D, Danielson CFM, Rothenberger SS, et al. Kasabach-Merritt syndrome with profound platelet support. AJCP. 1993;99(5):628-630.
26. Stuckey-Schrock K, Hayes BL, Georg CM. Community-acquired pneumonia in children. American Family Physician. 2012;86(7):661-667.
27. Hicks, MJ, Flaitz CM. The role of antibiotics in platelet dysfunction and coagulopathy. International Journal of Antimicrobial Agents. 1993;2(3):129–149.
28. Kotte W, Scharfe V. Drug effect on the rotation thromboelastogram in newborn infants. Folia Haematol Int Mag Klin Morphol Blutforsch. 1983;110(1):86-93.
29. Burroughs SF, Johnson GJ. Beta-lactam antibiotic-induced platelet dysfunction: evidence for irreversible inhibition of platelet activation in vitro and in vivo after prolonged exposure to penicillin. Blood. 1990;75;7: 1473-80.
30. Cazzola M, Materia MG, Santangelo G. Effects of some cephalosporins and teicoplanin on platelet aggregation. Int J Clin Pharmacol Res. 1993;13(2):69-73.
31. Kariyazono H, Nakamura K, Shinkawa T. Inhibitory effects of antibiotics on platelet aggregation in vitro. Hum Exp Toxicol. 1997;16(11);662-666.
32. Frese A, Rinke D, Künnecke M. Platelet aggregation during abdominal surgery in an experimental pig model: the effects of presurgical antibiotic protocols and volume replacement with hydroxyethyl starch. Thromb Res. 2000;97(3):143-151.
33. Sattler FR, Weitekamp MR, Seyegh A, Ballard JO. Impaired hemostasis caused by beta-lactam antibiotics. The American Journal of Surgery. 1988;155(5):30–39.